Micro RNAs (miRNAs) play a critical role in hematopoiesis and may have clinical relevance as therapeutic targets in lymphoma. Two major therapeutic strategies dominate: the first is to utilize miRNA mimicking to restore down-regulated miRNAs, e.g. tumor suppressors, such as miR-34 or let-7. The second strategy is to inhibit over-expressed miRNAs, such as miR-21 or miR-155.